CN104853752B - 嘧啶二酮衍生物化合物的制剂 - Google Patents

嘧啶二酮衍生物化合物的制剂 Download PDF

Info

Publication number
CN104853752B
CN104853752B CN201380066499.XA CN201380066499A CN104853752B CN 104853752 B CN104853752 B CN 104853752B CN 201380066499 A CN201380066499 A CN 201380066499A CN 104853752 B CN104853752 B CN 104853752B
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
compound
pharmaceutically acceptable
methanesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380066499.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104853752A (zh
Inventor
李艳霞
高坪
石屹
H.侯
M.麦卡普罗
K.A.米多斯
G.G.张
高忆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to CN201811208736.2A priority Critical patent/CN109260207A/zh
Publication of CN104853752A publication Critical patent/CN104853752A/zh
Application granted granted Critical
Publication of CN104853752B publication Critical patent/CN104853752B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380066499.XA 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂 Expired - Fee Related CN104853752B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811208736.2A CN109260207A (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
US61/715766 2012-10-18
PCT/US2013/065760 WO2014063101A1 (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811208736.2A Division CN109260207A (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Publications (2)

Publication Number Publication Date
CN104853752A CN104853752A (zh) 2015-08-19
CN104853752B true CN104853752B (zh) 2018-10-23

Family

ID=49554481

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380066499.XA Expired - Fee Related CN104853752B (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂
CN201811208736.2A Pending CN109260207A (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811208736.2A Pending CN109260207A (zh) 2012-10-18 2013-10-18 嘧啶二酮衍生物化合物的制剂

Country Status (11)

Country Link
US (2) US9629841B2 (enExample)
EP (1) EP2908808A1 (enExample)
JP (2) JP6266635B2 (enExample)
CN (2) CN104853752B (enExample)
AU (1) AU2013330993B2 (enExample)
BR (1) BR112015008927A2 (enExample)
CA (1) CA2888883A1 (enExample)
EA (2) EA032913B1 (enExample)
MX (1) MX2015004973A (enExample)
SG (1) SG11201503051QA (enExample)
WO (1) WO2014063101A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20230119355A1 (en) * 2020-03-05 2023-04-20 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
WO2009039127A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
WO2011109274A1 (en) * 2010-03-01 2011-09-09 Concert Pharmaceuticals Inc. Fluorouracil derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1083885T3 (da) 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
OA12124A (en) 1999-12-23 2006-05-05 Pfizer Prod Inc Pharmmaceutical compositions providing enhanced drug concentrations.
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20070082952A1 (en) * 2005-10-06 2007-04-12 Benjamin Eric J Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
SG2014011670A (en) * 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
WO2009039127A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
WO2011109274A1 (en) * 2010-03-01 2011-09-09 Concert Pharmaceuticals Inc. Fluorouracil derivatives

Also Published As

Publication number Publication date
AU2013330993A1 (en) 2015-05-07
EA032913B1 (ru) 2019-08-30
CN104853752A (zh) 2015-08-19
SG11201503051QA (en) 2015-05-28
AU2013330993B2 (en) 2018-03-01
US20140113921A1 (en) 2014-04-24
US9629841B2 (en) 2017-04-25
EA201791354A2 (ru) 2017-11-30
JP6266635B2 (ja) 2018-01-24
JP2015534985A (ja) 2015-12-07
EA201590752A1 (ru) 2016-02-29
WO2014063101A1 (en) 2014-04-24
EA201791354A3 (ru) 2018-03-30
MX2015004973A (es) 2015-07-17
JP2018065858A (ja) 2018-04-26
US10201542B2 (en) 2019-02-12
EA028481B1 (ru) 2017-11-30
BR112015008927A2 (pt) 2017-07-04
CA2888883A1 (en) 2014-04-24
EP2908808A1 (en) 2015-08-26
US20170181973A1 (en) 2017-06-29
CN109260207A (zh) 2019-01-25

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
TWI660748B (zh) 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP2010534220A (ja) ジヒドロピリジンカルシウムチャネル拮抗薬を含有する改善された医薬組成物およびその調製方法
JP2022548688A (ja) Ｔｙｋ２阻害薬の徐放性剤形
US8168221B2 (en) Composition 064
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
US20220347102A1 (en) Pharmaceutical composition comprising enzalutamide
JP2014196334A (ja) クエチアピンを含む徐放性医薬組成物
US10201542B2 (en) Formulations of pyrimidinedione derivative compounds
KR20180097623A (ko) 아프레밀라스트 서방형 제제
US9968607B2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
US20190091204A1 (en) Compositions of deferasirox
JP2008543723A (ja) ロシグリタゾンを含む経口製剤
EP4058025A1 (en) Pharmaceutical compositions comprising ticagrelor
WO2022153330A1 (en) Pharmaceutical compositions comprising acalabrutinib
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
KR20250110202A (ko) 변형-방출 실로도신 조성물 및 남성 피임 방법에서 이의 용도
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
WO2025108313A1 (zh) 包含egfr抑制剂的药物组合物
KR20160141045A (ko) 보센탄을 함유한 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181023

Termination date: 20191018

CF01 Termination of patent right due to non-payment of annual fee